Varenicline is a nicotinic acetylcholine receptor (nAChR) agonist used to treat nicotine addiction, but a live debate persists concerning its mechanism of action in reducing nicotine consumption. Although initially reported as a4b2 selective, varenicline was subsequently shown to activate other nAChR subtypes implicated in nicotine addiction including a3b4. However, it remains unclear whether activation of a3b4 nAChRs by therapeutically relevant concentrations of varenicline is sufficient to affect the behavior of cells that express this subtype. We used patch-clamp electrophysiology to assess the effects of varenicline on native a3b4* nAChRs (asterisk denotes the possible presence of other subunits) expressed in human adrenal chromaffin cells and compared its effects to those of nicotine. Varenicline and nicotine activated a3b4* nAChRs with EC 50 values of 1.8 (1.2-2.7) lM and 19.4 (11.1-33.9) lM, respectively. Stimulation of adrenal chromaffin cells with 10 ms pulses of 300 lM acetylcholine (ACh) in current-clamp mode evoked sodium channel-dependent action potentials (APs). Under these conditions, perfusion of 50 or 100 nM varenicline showed very little effect on AP firing compared to control conditions (ACh stimulation alone), but at higher concentrations (250 nM) varenicline increased the number of APs fired up to 436 AE 150%. These results demonstrate that therapeutic concentrations of varenicline are unlikely to alter AP firing in chromaffin cells. In contrast, nicotine showed no effect on AP firing at any of the concentrations tested (50, 100, 250, and 500 nM). However, perfusion of 50 nM nicotine simultaneously with 100 nM varenicline increased AP firing by 290 AE 104% indicating that exposure to varenicline and nicotine concurrently may alter cellular behavior such as excitability and neurotransmitter release. Keywords: a-conotoxin, nicotine addiction, nicotinic receptor, varenicline. J. Neurochem. (2017) 140, 37-52.
require co-assembly with either a different a subunit or with a b subunit, but some subunits, including a7 and a9, are capable of forming homomeric nAChRs where the receptor is formed from a single gene product (Elgoyhen et al. 1994; Gerzanich et al. 1994) .
Varenicline is a nAChR agonist used as a smoking cessation aid. Its mechanism of action for reducing the consumption of nicotine is thought to be mediated by partial agonism of the a4b2 subtype (Rollema et al. 2007 ). However, it was later shown that varenicline also activates other nAChR subtypes implicated in nicotine addiction including a6b2, a3b4, and a7 (Mihalak et al. 2006; Capelli et al. 2011; Tammimaki et al. 2012) . Nicotinic compounds that have activity on off-target subtypes are known to produce significant side effects. This is particularly problematic for compounds that activate the a3b4 subtype because of its prominent expression in ganglionic neurons of the peripheral nervous system (Poth et al. 1997; Zhou et al. 2002; Mao et al. 2006; David et al. 2010; Hone et al. 2012) . Notably, the cardiovascular (CV) side-effect profile of varenicline suggests that it may be acting on ganglionic a3b4 nAChRs.
Although heterologously expressed a3b4 nAChRs have been shown to be activated by varenicline (Mihalak et al. 2006; Stokes and Papke 2012; Campling et al. 2013; Rollema et al. 2014) , sparse information is available concerning its activity on native human a3b4 nAChRs. Thus, it would be desirable to evaluate varenicline's effects on a cell population that endogenously expresses a3b4 given this subtype's relevance to nicotine addiction (Dwoskin et al. 2009; George et al. 2012; Jackson et al. 2013; Slimak et al. 2014) . The ideal neuronal population in which to study the effects of varenicline may be that of the medial habenula where a3b4 nAChRs are known to be expressed. These neurons are thought to be involved in reward pathways linked to nicotine addiction (Dani and De Biasi 2013; Antolin-Fontes et al. 2015) and thus may be a neuronal population targeted by varenicline. Unfortunately, as with other neuronal populations, medial habenular neurons coexpress multiple nAChR subtypes including a4b2* and a6b2* (Grady et al. 2009; Scholze et al. 2012; Shih et al. 2014) complicating their use for the study of native a3b4 nAChRs in isolation. We recently showed that human chromaffin cells predominantly express the a3b4* subtype and express few, if any, nAChRs with canonical a x b2 ligandbinding sites (Hone et al. 2015) . Importantly, these cells lack a4-and a6-containing nAChRs and thus represent an excellent population in which to assess the effects of varenicline on native a3b4 nAChRs.
A central goal of this study was to address the running debate on whether or not therapeutic concentrations (≤ 100 nM) of varenicline are capable of altering the response of a cell that expresses a3b4 nAChRs. The results show that in chromaffin cells, concentrations of varenicline ≤ 100 nM fail to alter AP firing and only concentrations > 100 nM were capable of increasing AP firing. In contrast, nicotine showed no effects on AP firing at concentrations ≤ 500 nM. However, nicotine (50 nM) in combination with varenicline (100 nM) did increase AP firing. These findings suggest that varenicline alone is unlikely to affect the behavior of cells that express a3b4 nAChRs, but may show effects when combined with nicotine. Our results offer important information in the context of nicotine addiction treatment with varenicline and nicotine replacement therapeutics (NRT) and may help guide the development of improved therapy strategies.
Materials and methods

Reagents
Acetylcholine chloride, (À)-nicotine tartrate, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), amphotericin B, penicillin/ streptomycin, protease type XIV, collagenase Type I, poly-D-lysine hydrobromide, Red Blood Cell Lysis solution, dimethylsulfoxide, and all salts were purchase from Sigma-Aldrich (St. Louis, MO, USA). Varenicline tartrate and tetrodotoxin citrate (TTX) were purchased from Tocris Bioscience (Abindgon, UK). Dulbecco's Modified Eagle 0 s Medium and Glutamax were purchased from Life Technologies (Carlsbad, CA, USA). Fetal bovine serum was from LabClinics (Barcelona, Spain) and the D-glucose from Panreac (Barcelona, Spain).
Peptide synthesis
The a-conotoxins (a-Ctxs) BuIA(T5A,P6O) (Azam et al. 2010) and ArIB(V11L,V16D) (Whiteaker et al. 2007 ) were synthesized as previously described (Cartier et al. 1996) . a-Ctx TxID was synthesized using an Apex 396 automated peptide synthesizer (AAPPTec, Louisville, KY) according to previously described methods (Hone et al. 2013) .
Human adrenal chromaffin cell isolation and culture Human adrenal chromaffin cells were isolated from male and female organ donors and cultured as previously described (Hone et al. 2015) . The use of human tissue was approved by the Universidad Aut onoma de Madrid 0 s institutional review board and by the review boards of each of the hospitals. Briefly, the cells were isolated by digestion of adrenal medullary tissue using protease type XIV followed by incubation with collagenase type I. The isolated cells were maintained in Dulbecco's Modified Eagle's Medium culture medium at 37°C in an incubator under an atmosphere of 95% air and 5% CO 2 for up to 7 days. The culture medium was changed daily by exchanging approximately 70% of the solution with fresh medium. The age of the male donors was 55.7 AE 7.4 SDM (n = 12) years and 47.0 AE 16.8 SDM (n = 2) years for the female donors.
Patch-clamp electrophysiology
To conduct electrophysiology experiments, the cells were gravity perfused with an extracellular solution composed of 145 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM D-glucose, and 10 mM HEPES. The osmolarity was 315 mOsM and the pH was adjusted to 7.4 with NaOH. The flow rate was 1.5 mL/min and was delivered by means of a polyethylene tube with an inner diameter of 0.58 mm. The outlet of this tube was place close to the cell of interest to ensure rapid solution exchange. Patch electrodes were pulled from borosilicate glass capillaries (Kimbal Chase, cat. #3400-99) using a P97 pipette puller (Sutter Instruments, Novato, CA, USA). The electrodes had resistances between 1.5 and 3.0 MΩ when filled with an internal electrode solution (145 mM Kglutamate, 10 mM NaCl, 1 mM MgCl 2 , 10 mM D-glucose, and 10 mM HEPES; pH adjusted to 7.2 with KOH; observed osmolarity 322 mOsM). Under these conditions, the average resting membrane potential (RMP) of the cells was À60.4 AE 0.9 mV (SEM of n = 29). To initiate whole-cell recordings, a stock solution of 0.5 mg/mL amphotericin B was prepared daily in dimethyl sulfoxide. Five microliter of this stock solution was added to 500 lL of intracellular solution, ultrasonicated, and used to back fill the patch electrodes. All experiments were performed under a sodium lamp for light and at 22-24°C. A HEKA EPC10 amplifier (HEKA Electronik, Lambrect, Germany) was used to record agonist-evoked responses. The signals were sampled at 10 kHz and filtered at 1 kHz through a Bessel filter. The average capacitance of the cells studied was 8.9 AE 3.0 pF (SDM of n = 66) and was compensated electronically. Series resistances between 7 and 15 MΩ were obtained and were compensated electronically by 70-80% in voltage-clamp mode. In current-clamp mode, the resistance was compensated by ≥ 80% using the bridge balance feature of Patch Master. Agonists were applied to the cell in two ways depending on the type of experiment. For all currentclamp experiments, a Picospritzer III (General Valve Corp., Fairfield, NJ, USA) was used to apply ACh to the cell by means of pressure ejection (15 w) through a glass capillary tube (World Precision Instruments, Sarasota, FL, USA; cat. 1B200F-4) that had been pulled to obtain an opening of 1-2 lm in diameter and filled with extracellular solution containing 300 lM ACh. For agonist studies in voltage-clamp mode, a multi-barrel pipette was constructed using polyethylene tubing each with an inner diameter of 0.4 mm. A single polyethylene tube with an inner diameter of 0.28 mm was used for the outlet. The flow rate of the perfusion system was approximately 850 lL/min. The agonist pulses were controlled by a valve controller triggered by the amplifier. For the agonist concentration-response experiments, 500 ms pulses of agonist were applied every 3 min. The cells were first stimulated with 300 lM ACh until steady baseline responses were achieved and then different agonists of interest were applied in ascending concentrations.
Xenopus oocyte electrophysiology
Complete methods for conducting two-electrode voltage-clamp electrophysiology of Xenopus laevis oocytes-expressing nAChRs have been previously described (Hone et al. 2009 ). Briefly, to express a3b4 nAChRs the oocytes were injected with water containing 1 ng of cRNA encoding human a3 and 1 ng encoding b4 subunits. To express a4b2 and a7 nAChRs, 10 ng of cRNA for both a4 and b2 subunits was injected and 41 ng of cRNA for a7. The oocytes were incubated for 1-3 days at 17°C prior to use. To conduct electrophysiology experiments, the oocytes were mounted in a 30 lL perfusion chamber and stimulated with 1 s pulses of 300 lM ACh once every 60 s until a steady baseline response was achieved. The control solution was then changed to one containing a-Ctx TxID and the responses to ACh monitored for inhibition. For the evaluation of TxID and BuIA(T5A,P6O) on the a7 subtype, the toxin was applied in a static bath for 5 min and the responses in the presence of the toxin were compared to control responses in the absence of toxin. Agonist concentration-response curves were obtained as previously described .
Data analysis
Agonist concentration-response analyses were performed using GraphPad Prism (La Jolla, CA, USA). The responses were normalized according to the following procedures: the current amplitudes for ACh-evoked responses for each cell were fit with the Hill equation to obtain the calculated plateau value for activation. The difference between the calculated plateau value and the observed response obtained at 300 lM was ≤ 3% in all cells indicating that 300 lM ACh elicited a maximal response. The observed ACh-evoked responses were then normalized to the calculated plateau value to obtain a percent response. As 300 lM ACh was determined to produce a maximal response, in subsequent experiments the responses of all other agonists were normalized to those obtained by 300 lM ACh in the same cell. Agonist concentration-response experiments were conducted in the presence of the selective a7 nAChR antagonist a-Ctx ArIB(V11L,V16D) (Whiteaker et al. 2007; Innocent et al. 2008) to ensure that only a3b4* nAChRs were activated. For the evaluation of the effects of TTX, a-Ctxs, nicotine, and varenicline on ACh-evoked APs in current-clamp experiments, a response was considered an AP when the membrane depolarization exceeded 0 mV, the approximate E rev for nAChR channels (Stauderman et al. 1998; Chavez-Noriega et al. 2000) , to distinguish the depolarization component produced by VGICs from that produced by the nAChRs. An analysis of variance (ANOVA) and a Fischer's LSD were used to determine statistical significance for the effects of varenicline and nicotine on AP firing and a t-test was used to compare changes in the RMP. Significance was determined at the 95% confidence interval. The numbers of cells per experiment (n) are reported as the SEM unless otherwise indicated. GraphPad Prism was also used to determine the IC 50 values for inhibition of the ACh-evoked responses in adrenal chromaffin cells and Xenopus oocytes by TxID.
Results
Varenicline and nicotine evoke whole-cell currents in human adrenal chromaffin cells The EC 50 value for activation of heterologously expressed human a3b4 nAChRs by varenicline has been reported to be in the range 2.0-25.0 lM and 10.0-200.0 lM for nicotine (Stokes and Papke 2012; Tammimaki et al. 2012; Campling et al. 2013; Rollema et al. 2014) . We confirmed the activity of varenicline on human a3b4 and a4b2 nAChRs expressed in Xenopus oocytes where it was observed to be more potent but less efficacious on a4b2 than a3b4 nAChRs (Fig. S1 ). The EC 50 value for activation of the a4b2 subtype was 54.3 (30.3-97.4) nM but was only 7 AE 0.4% as efficacious compared to ACh. The EC 50 value for the a3b4 subtype was determined to be 26.3 (21.0-32.9) lM and showed a 96 AE 4% efficacy relative to ACh. These data confirm varenicline's partial agonism of human a4b2 nAChRs and full agonism of the a3b4 subtype.
Despite a good amount of available information concerning the pharmacology of heterologously expressed human nAChRs, very little information is available for native human a3b4 nAChRs. To determine if human adrenal chromaffin cell a3b4* nAChRs display a pharmacology similar to heterologously expressed a3b4 nAChRs, we assessed the ability of varenicline and nicotine to evoke currents in patchclamped human adrenal chromaffin cells and compared their potencies to that of ACh. Varenicline was found to be 10-fold more potent and a full agonist (103 AE 7%) relative to ACh (Fig. 1a) . Nicotine was only slightly more potent (~2-fold) and behaved as a partial agonist (80 AE 3%) relative to ACh (Fig. 1a) . The maximal efficacy of varenicline and nicotine appeared to be limited by open-channel block as evidenced by currents that, in some cells, showed a slight increase in amplitude at the end of the drug application (not shown). Importantly, therapeutically relevant concentrations (100 nM) of both agonists failed to evoke substantial wholecell currents (Fig. 1a-c) . A summary of the data obtained for ACh, nicotine, and varenicline is presented in Table 1 .
Brief pulses of ACh evoke APs in human adrenal chromaffin cells
The experiments shown in Fig. 1 provided basic parameters for the potency and efficacy of varenicline and nicotine on native a3b4* nAChRs. Significant whole-cell currents evoked by varenicline and nicotine were only observed at concentrations ≥ 1 lM. Nevertheless, activation of nAChRs by low concentrations of agonists may alter cell excitability. We therefore sought to determine if lower concentrations of varenicline and nicotine showed effects on AP firing in Table 1 . human adrenal chromaffin cells. A stimulation protocol using brief puffs of ACh to evoke APs was employed to mimic the natural stimulus the chromaffin cell would receive in vivo. This protocol consisted of stimulating the cells with 10 or 25 ms puffs of 300 lM ACh at 0.2 Hz. The perfusion solution outlet was placed as close as possible to the cell such that the ACh response was terminated in~500 ms. Figure 2 (a) shows the responses evoked by this stimulation protocol in a cell voltage clamped at À60 mV (near the RMP). Figure 2(b) shows the responses to the same ACh stimulation protocol but in current-clamp mode at the RMP. This protocol evoked APs that were sodium channel-dependent as evidenced by the fact that the depolarization of the membrane potential triggered by ACh could be reduced to 60 AE 4% (n = 4) of control values by the sodium channel antagonist TTX (Fig. 2c) . Similarly, after washout of the TTX, changes in the depolarization of the membrane could also be reduced and the generation of APs prevented by simultaneous perfusion of the a3b4* nAChR antagonist a-Ctx BuIA(T5A,P6O) (1 lM) and the a7 antagonist ArIB(V11L,V16D) (100 nM) (D). In the presence of the a-Ctxs, the ACh-induced change in membrane potential was reduced to 33 AE 8% (n = 4) of control amplitudes. This residual response indicated that a fraction of the nAChRs remained uninhibited. To determine the fraction that was not blocked, we reassessed the actions of BuIA(T5A,P6O) in voltage-clamp mode (V h = À60 mV) in the same cells. The cells were perfused with extracellular solution for > 20 min to wash out the a-Ctxs from the previous application. Afterward, the cells were again exposed to BuIA(T5A,P6O) (1 lM) which inhibited 97 AE 0.3% (n = 3) of the ACh-evoked response leaving on average À178 AE 0.7 pA (n = 3) of current (Fig. 3) . Higher concentrations were not tested owing to the amount of BuIA(T5A,P6O) that would have been required. Therefore, to determine if the remaining response was potentially mediated by other nAChRs in addition to a3b4* nAChRs, we tested the recently described a-Ctx TxID. This peptide has been shown to potently inhibit heterologously expressed rat a3b4 but shows essentially no inhibition of a7 nAChRs at 10 lM (Luo et al. 2013) . To ensure that this selectivity is conserved between rat and human, we first tested TxID on Xenopus oocytes expressing either human a3b4 or a7 nAChRs. TxID was found to inhibit oocyte-expressed human a3b4 nAChRs with an IC 50 value of 8.7 (7.8-9.7) nM (n = 4, Fig. 4a ). In contrast, very little inhibition by TxID of the ACh-evoked response was observed in oocytesexpressing a7 nAChRs (Fig. 4a) . The a7-mediated responses to ACh were 93 AE 5% (n = 5) of control values after a 5 min application of 30 lM TxID. BuIA(T5A,P6O) was also tested on oocytes-expressing a7 nAChRs and no inhibition of the ACh-evoked response was observed at 10 lM (99 AE 3%, n = 5; data not shown). Thus, the expectation was that the portion of the whole-cell current mediated by a3b4* nAChRs in human adrenal chromaffin cells would be completely inhibited and any residual currents would be from activation of other non-a3b4* subtypes. TxID was tested on human adrenal chromaffin cells and was found to inhibit the ACh-evoked responses with an IC 50 value of 24.1 (20.1-28.5) nM (n = 4; Fig. 4c ). At 1 lM the a-Ctx nearly completely inhibited (99 AE 0.3%, n = 4) the ACh-evoked responses (Fig. 4d) . The absence of residual currents indicates that under the conditions utilized in this study, the ACh-evoked APs in human adrenal chromaffin cells are mediated by a3b4* nAChRs.
Varenicline and nicotine both inhibit ACh-evoked APs and evoke APs in the absence of ACh stimulation A series of experiments were conducted to evaluate the effects of varenicline and nicotine on AP firing in human adrenal chromaffin cells. The cells were stimulated using the protocol described in Fig. 2 with the exception that the duration of the ACh pulse was reduced to 10 ms. Approximate EC 50 concentrations of each compound were chosen to determine if intrinsic differences on AP firing could be observed. Under these conditions, perfusion of 4 lM varenicline reduced the number of ACh-evoked APs to 34 AE 10% (n = 6) of control values (Fig. 5a) . After washout by perfusion with control solution (Fig. 5d ), the cells were again exposed to 4 lM varenicline for 1 min (Fig. 5e ). In the absence of ACh stimulation, varenicline evoked 8 AE 3 APs in 5 cells and no APs in 1 cell. Next, we tested an approximate EC 50 concentration of nicotine (20 lM) and observed effects on AP firing similar to those observed with varenicline. Nicotine evoked a burst of APs in 4/6 cells and in all cells completely abolished the ability of ACh to evoke APs after a~10-15 s exposure (Fig. 6a-c) . The number of ACh-evoked APs during the 1 min perfusion with nicotine was reduced to 38 AE 9% (n = 6) compared to control conditions (Fig. 6b) . Nicotine was also capable of evoking APs in the absence of ACh stimulation in 5/7 cells. In these 5 cells, nicotine elicited 8 AE 2 APs during the 1 min perfusion (Fig. 6e) . Interestingly, in both the ACh stimulated and nonstimulated conditions the membrane potential remained depolarized for the 1 min duration of exposure to the agonists. The membrane potential at the end of the 1 min perfusion of 4 lM varenicline was À17 AE 1 mV (n = 6; Fig. 5e ) and -15 AE 2 mV (n = 6) in the presence of 20 lM nicotine (Fig. 6e) . In a separate group of cells, we tested nicotine and varenicline in voltage-clamp mode (V h = À60 mV) and found that 4 lM varenicline reduced the ACh-evoked currents to 8 AE 3% (n = 4) of control values and 20 lM nicotine reduced currents to 13 AE 3% after a 1 min perfusion (Fig. 7) . These results suggest that activation of only a fraction of the a3b4* nAChRs is required to maintain the membrane in a depolarized state.
nM concentrations of varenicline, but not nicotine, evoke APs in human adrenal chromaffin cells In the previous experiments, we found that~EC 50 concentrations of varenicline and nicotine altered the cells ability to fire APs in response to ACh and were capable of evoking APs in the absence of ACh stimulation. However, EC 50 concentrations of these compounds are not achieved clinically in the plasma of humans. Concentrations of varenicline achieved in human plasma following a daily 1-2 mg dose are approximately 50-100 nM (Faessel et al. 2006; Ravva et al. 2009; Kikkawa et al. 2011) . Nicotine concentrations rise to 50-500 nM in tobacco users, but in the clinical setting, only~90-100 nM concentrations are achieved from the use of nicotine patches (Gorsline et al. 1992; Sobue et al. 2005) . To determine if clinically relevant concentrations of varenicline affected the chromaffin cell's response to stimulation with ACh, we perfused the cells first with 50 nM followed by 100 nM of the drug. Higher non-clinical concentrations of 250 and 500 nM varenicline were also tested to compare responses obtained with the same concentrations of nicotine. The cells were continuously perfused over the entire range of concentrations and each concentration was perfused for 1 min duration each. Under these conditions, no significant increases in the number of APs fired were observed in the presence of 50 or 100 nM varenicline (125 AE 25%, n = 6, p > 0.05, Fig. 8b and 204 AE 99%, n = 6, p > 0.05, Fig. 8c , respectively) compared to control conditions (Fig. 8a) . However, robust increases were observed in the presence of 250 nM varenicline (436 AE 150%, n = 6, ***p < 0.001, Fig. 8d ). At a concentration of 500 nM varenicline, the number of APs fired was 225 AE 59% (p > 0.05, Fig. 8e ) of control values. These results suggest that therapeutically relevant concentrations of varenicline are unlikely to alter the adrenal chromaffin cells' response to ACh. Nevertheless, in the absence of ACh stimulation, fluctuations in the membrane potential of the cell were observed in the presence of 50 and 100 nM varenicline ( Fig. 8g and h ) indicating that varenicline produced low levels of a3b4* nAChR activation at these concentrations. These fluctuations did not result in a statistically significant number of APs fired (1.8 AE 1.8; p > 0.05, n = 6 and 0.25 AE 0.25, p > 0.05, n = 6, for 50 and 100 nM, respectively, Fig. 8f-h ). In addition, no changes in the RMP were observed in the presence of 50 or 100 nM varenicline compared to controls (À62.4 AE 0.9 mV and À60.6 AE 1.5 mV vs. À65.2 AE 1.4 mV, respectively; p > 0.5; n = 5; Fig. 8f-h ). However, 250 and 500 nM varenicline depolarized the membrane such that the threshold for the firing of APs was achieved. The membrane potential of the cell in the presence of 250 and 500 nM varenicline was depolarized to À36.3 AE 3.0 mV (n = 6) and À35.3 AE 5.6 mV (n = 6) which resulted in the cell firing 130 AE 15 (**p < 0.01, n = 6) and 49 AE 16 (p > 0.05, n = 6) APs, respectively ( Fig. 8i and j) .
In contrast to the results observed with varenicline, nicotine showed very little effect on AP firing. No significant increases in the number of APs fired were observed at any of the nicotine concentrations tested (50, 100, 250, and 500 nM; p > 0.05; n = 6; Fig. 9a-e) or changes in the RMP (À62.0 AE 2.3 mV, À61.7 AE 2.5 mV, À58.2 AE 5.2 mV, and À60.2 AE 3.0 mV vs. À61.3 AE 2.7 mV, respectively; p > 0.5; n = 6; Fig. 9f-j) . Nevertheless, nicotine was not completely without effect as evidenced by fluctuations of the membrane potential observed in the presence of 250 and 500 nM nicotine. These fluctuations were particularly evident in traces where nicotine was perfused alone in the absence of ACh stimulation ( Fig. 9i  and j) .
Simultaneous perfusion of 50 nM nicotine together with 100 nM varenicline increases APs firing in human adrenal chromaffin cells Figure 2 demonstrates that varenicline is~10-fold more potent at activating chromaffin cell a3b4* nAChRs than nicotine and this may account for the relative lack of effect observed with nicotine ( Fig. 9) compared to varenicline ( Fig. 8) when perfused at the same concentrations. Nevertheless, nicotine in the presence of varenicline may have additive effects on AP firing. Such a condition often occurs clinically during the initial stages of varenicline treatment when patients continue to use tobacco or when NRTs are used as an adjunct therapy. When we perfused the cells with 50 nM nicotine together with 100 nM varenicline we observed a 290 AE 104% (*p < 0.05, n = 5; Fig. 10b ) increase in the number of APs fired compared to control conditions (Fig. 10a) . However, a statistical comparison of the values obtained under these conditions to those obtained by perfusion with 100 nM varenicline alone (Fig. 8b) indicated no additive effects of nicotine on AP firing (p > 0.05). Increasing the concentrations of nicotine further to 100, 250, and 500 nM resulted in responses that were 155 AE 72% (p > 0.05, n = 5, Fig. 10c ), 120 AE 33% (p > 0.05, n = 5, Fig. 10d ), and 155 AE 22% (p > 0.05, n = 5, Fig. 10e ), respectively, of control conditions (Fig. 10a) . Repeating this protocol, but without ACh stimulation, perfusion of 50 nM nicotine together with 100 nM varenicline resulted in the cells firing an average of 61 AE 31 APs (***p < 0.001, n = 4; Fig. 10g ) compared to control conditions (Fig. 10f) . Further increases in nicotine concentrations to 100, 250, and 500 nM evoked 16 AE 9, 11 AE 4, and 23 AE 9 APs, respectively, but these values were not statistically significant (p > 0.05, n = 4; Fig. 10h-j) . We also compared the number of APs fired in response to perfusion with 50 nM nicotine together with 100 nM varenicline to perfusion with 100 nM varenicline alone (Fig. 8g) and found no statistical difference (p > 0.05) again suggesting no additive effects of nicotine of AP firing. Lastly, a statistically significant change in the steady-state membrane potential of the cells during perfusion with 50, 100, 250, and 500 nM nicotine in the presence of 100 nM varenicline was observed. The RMPs under these conditions were À29.0 AE 3.4 mV (***p < 0.001, n = 4; Fig. 10g ), À32.5 AE 4.8 mV (**p < 0.005, n = 4; Fig. 10h ), À37.3 AE 6.6 mV (*p < 0.05, n = 4; Fig. 10i) , and À37.8 AE 6.3 mV (*p < 0.05, n = 4; Fig. 10j ), respectively, compared to control values (À58.3 AE 1.3 mV, Fig. 10f ).
Discussion
Nicotine is one of the most widely used drugs of abuse and the ubiquitous expression of nAChRs throughout the central and peripheral nervous systems means that multiple physiological processes may be affected by exposure to this alkaloid. Likewise, these systems may also be affected by administration of smoking cessation therapeutics such as varenicline. Varenicline's mechanism of action for reducing the consumption of nicotine is believed to be mediated by partial agonism of central nervous system a4b2 nAChRs (Coe et al. 2005; Rollema et al. 2010) . However, varenicline has also been shown to activate other human nAChR subtypes implicated in nicotine addiction including a6b2b3, a3b4, and a7 (Capelli et al. 2011; Bordia et al. 2012; Stokes and Papke 2012; Campling et al. 2013) . The reported potency and efficacy of varenicline on heterologously expressed human a3b4 nAChRs ranges from 2 to 25 lM (Stokes and Papke 2012; Campling et al. 2013; Rollema et al. 2014) . We found that varenicline activated native a3b4* nAChRs in human adrenal chromaffin cells with an EC 50 of~2 lM. We also found that varenicline behaved as a full agonist of native a3b4* nAChRs (Fig. 1a and c) similar to the activity reported by others (Campling et al. 2013; Jensen et al. 2014; Rollema et al. 2014) and in this study (Fig. S1 ) for heterologously expressed a3b4 nAChRs. Other reports suggest that varenicline acts as a partial agonist of a3b4 nAChRs (Stokes and Papke 2012; Arias et al. 2015) and its effects can be influenced by the particular subunit present in the 'auxiliary' 5th position of the receptor complex. For example, the presence of an a5 subunit has been reported to reduce efficacy (Stokes and Papke 2012; Tammimaki et al. 2012; Rollema et al. 2014) . Reports of nicotine efficacy also vary, but it has generally been shown to be a partial agonist of heterologously expressed human a3b4 nAChRs (Wang et al. 1996; George et al. 2012; Stokes and Papke 2012; Campling et al. 2013) in agreement with the results presented here for native a3b4* nAChRs in human adrenal chromaffin cells (Fig. 1a and b) . Nicotine's efficacy also can be influenced by the particular subunit present in the 5th position. As with varenicline, the presence of an a5 subunit reduces efficacy while a b2 subunit increases efficacy relative to ACh (Stokes and Papke 2012) . Interestingly, a5 and b2 subunit mRNA transcripts have been detected in human adrenal chromaffin cells leading to the possibility that more than one a3b4 nAChR subtype may be expressed by these cells (Hone et al. 2015) .
While both varenicline and nicotine activated whole-cell currents in human adrenal chromaffin cells, the concentrations at which these currents were evoked exceeded those that are normally achieved in human plasma during routine administration. Peak nicotine concentrations found in the plasma of smokers can reach~500 nM (Henningfield et al. 1993; Gourlay and Benowitz 1997; Benowitz et al. 2009 ), but concentrations of varenicline generally only reach~50-100 nM. Although unable to evoke substantial whole-cell currents at nM concentrations, low levels of nAChR activation by varenicline and nicotine may lower the threshold for firing APs by increasing the excitability of the cell membrane. We tested this hypothesis by examining the effects of varenicline and nicotine on human adrenal chromaffin cell's ability to fire APs either in response to ACh or by perfusion of the agonists alone. Stimulation of the cells in current-clamp mode by ms puffs of ACh evoked APs that could be inhibited by the sodium channel antagonist TTX or by nAChR antagonists (Fig. 2) . These APs were mediated by the a3b4* subtype as evidenced by experiments that showed that the a3b4 nAChR antagonist a-Ctx BuIA(T5A,P6O) inhibited >97% of the ACh-evoked currents in these cells (Fig. 3) . Additional experiments were performed using the potent and highly selective a3b4 antagonist a-Ctx TxID. This a-Ctx inhibited~99% of the ACh-evoked currents in both human chromaffin cells and in oocytes heterologously expressing human a3b4 nAChRs (Fig. 4a-d) . These experiments confirmed our previous report that a3b4* nAChR is the predominant subtype expressed by human adrenal chromaffin cells. (Hone et al. 2015) The effects of low level activation of nAChRs on membrane excitability are not easily measured in whole-cell voltage-clamp experiments. Voltage-clamp experiments measure the amount of current applied by the amplifier to keep the voltage of the membrane constant at an was -61.5 AE 2.8 mV (n = 6). Traces (a-e) and (f-j) are continuous with respect to time and each concentration was perfused for 1 min each. Note that the Y-axis is expanded in traces (f-j) compared to those in (ae) to better appreciate the fluctuations in V m produced by nicotine. In all traces, the X-axis values indicate time (s) and the Y-axis values indicate V m in mV; red dots indicate stimulation with ACh; AE, SEM. A one-way ANOVA with Fischer's LSD post hoc test was used to compare the number of APs fired in the presence of nicotine to control conditions (ACh stimulation alone or control solution alone) and changes in RMP were compared using a t-test; results were considered significant if the p value was < 0.05. of 100 nM varenicline. The average RMP for this series was -57.0 AE 1.6 mV (n = 6). Traces (a-e) and (f-j) are continuous with respect to time and each concentration was perfused for 1 min each. In all traces, the X-axis values indicate time (s) and the Y-axis values indicate V m in mV; red dots indicate stimulation with ACh; AE, SEM. A one-way ANOVA with Fischer's LSD post hoc test was used to compare the number of APs fired in response to perfusion with increasing concentrations of nicotine in the presence of 100 nM varenicline to control conditions (ACh stimulation alone or control solution alone) and changes in RMP were compared using a t-test; results were considered significant if the p value was < 0.05. A scatterplot showing the number of APs fired under each condition for all cells is shown in Fig. S2. experimentally set value. This is essential for isolating the activation of ligand-gated ion channels from the responses of VGICs. Current-clamp electrophysiology, on the other hand, can measure the response of the cell without artificially setting the voltage of the membrane and allows the cell to respond in a more physiological manner upon exposure to a particular stimulus. The response may include the recruitment of VGICs and may assess more closely the physiological response of the cell compared to whole-cell voltageclamp experiments. To assess the effects of varenicline and nicotine on membrane excitability, the cells were stimulated with 10 ms puffs of ACh to evoke APs and then perfused with either varenicline or nicotine over a range of concentrations to determine if therapeutically relevant concentrations produced an effect. For comparison, we first perfused varenicline or nicotine at high concentrations (~EC 50 values) and observed that varenicline and nicotine initially evoked a burst of APs but then inhibited the ability of the cell to fire APs in response to ACh by maintaining the cell membrane at depolarized potentials (Figs 5 and 6). Interestingly, the voltage of the membrane remained substantially depolarized throughout the 1 min exposure to the agonists. In voltageclamp mode, perfusion of the same concentrations of varenicline or nicotine inhibited the ACh-evoked currents by > 90% after a 1 min exposure (Fig. 7) . These observations, combined with those in Figs 2 and 3, suggest that activation of < 10% of the a3b4* nAChRs present in human adrenal chromaffin cells is sufficient to substantially affect membrane potential and aligns with previous results using ACh (Perez-Alvarez and Albillos 2007) . Similar effects have been observed in Xenopus laevis oocytes where continuous perfusion of varenicline (1 lM) resulted in steady-state currents mediated by a4b2 nAChRs that lasted for the duration of agonist exposure (Papke et al. 2011) .
In general, when therapeutically relevant concentrations (50 or 100 nM) of varenicline were perfused, no effect on the adrenal chromaffin cell's response to ACh stimulus was observed ( Fig. 8b and c) . However, when the cells were exposed to 250 nM varenicline, 83% (5/6) of the cells responded robustly with increased AP firing (Fig. 8d) . In contrast, cells perfused with nicotine up to 500 nM generally showed no alteration in their response to ACh (Fig. 9a-e) . Nevertheless, nicotine was not completely without effect as evidenced by increased fluctuations of the membrane potential which were particularly pronounced at 500 nM (Fig. 9j) . Thus, even in the absence of direct effects on ACh-evoked AP firing, low concentrations of varenicline and nicotine may increase the excitability of the cell membrane via activation of a3b4 nAChRs and may influence different cellular processes. Further experiments were performed to determine if nicotine exposure in the presence of varenicline would produce additive effects on the cells response to ACh. Such a circumstance might occur during concomitant use of varenicline and NRTs such as nicotine patches. We found that perfusion of nicotine (50 nM) in the presence of varenicline (100 nM) increased AP firing relative to control conditions (290 AE 104%) ( Fig. 10a and b) , but no statistical differences were found when these values were compared to those obtained by perfusion with 100 nM (204 AE 99%) varenicline alone (Fig. 8c) .
Overall, the results obtained in this study suggest that at therapeutic concentrations, varenicline alone is unlikely to substantially alter AP firing in chromaffin cells. Concentrations > 100 nM (Fig. 8d) , however, did evoke a significant number of APs over control conditions (Fig. 8a) . This observation seems to correlate with clinical data in that doses of varenicline that produce plasma concentrations > 100 nM produce significant side effects. We also note that concentrations > 100 nM would produce very little if any increase in a4b2 receptor activation (Fig. S1 ). This observation is supported by data that demonstrate that a single 0.5 mg dose of varenicline produces concentrations in the brain that saturate a4b2 receptor binding sites (Lotfipour et al. 2012 ). Thus, concentrations > 100 nM or the addition of another nicotinic receptor agonist such as nicotine may not have added benefits in terms of a4b2 receptor activity. Furthermore, clinical data examining NRTs such as gum or lozenges containing nicotine or nicotine patches in combination with varenicline are ambiguous with respect to smoking cessation rates (Koegelenberg et al. 2014; Baker et al. 2016) .
Meta-analyses of clinical data suggest that varenicline use is associated with increased CV events in a small percentage of patients (Singh et al. 2011; Harrison-Woolrych et al. 2012) , but the exact mechanisms by which these side effects are produced remain unknown. We observed that nM concentrations of varenicline caused fluctuations in the membrane potential of adrenal chromaffin cells suggesting an increase in membrane excitability as a result of low levels of nAChR activation. It is tempting to speculate that treatment with varenicline may increase chromaffin cell excitability, and hence catecholamines release, sufficiently to elevate circulating catecholamine levels. Another possibility is that nicotine in combination with varenicline may increase cell excitability sufficiently to increase catecholamine release and thus cause CV side effects. This circumstance may occur in patients who begin treatment with varenicline and continue to use nicotine containing products. However, to our knowledge, direct effects of varenicline in combination with nicotine, either from smoking or NRTs, on circulating catecholamine levels in humans have not been examined. Thus, it remains unclear whether potential alterations in the release of catecholamines produced by combination therapy would elevate plasma levels sufficiently to produce CV effects. More data are needed to determine if varenicline use is associated with elevated catecholamine levels and whether or not such increases would be significant enough to produce CV side effects.
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Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 . Varenicline is a partial agonist of human a4b2 and a full agonist of a3b4 nAChRs expressed in Xenopus oocytes. Figure S2 . Scatterplot analyses of the number of APs fired by human adrenal chromaffin cells under various pharmacological conditions.
